Cargando…
Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: an in vitro and xenograft mouse-model study
BACKGROUND: MicroRNAs (miRNAs) acting as tumour suppressors or oncogenes, known as oncomiRs, are a promising new focus in targeted therapies for cancer. Approximately 16% of breast cancer patients have pre-existing diabetes. Breast cancer with type 2 diabetes mellitus (BDM) is provided with its uniq...
Autores principales: | Li, Zhihua, Min, Liangliang, Chen, Lu, Hu, Yangyang, Luan, Wenjing, Li, Cong, Xiong, Qiuyun, Huang, Kedi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189168/ https://www.ncbi.nlm.nih.gov/pubmed/35706821 http://dx.doi.org/10.21037/tcr-22-824 |
Ejemplares similares
-
MiR-29c-3p, a target miRNA of LINC01296, accelerates tumor malignancy: therapeutic potential of a LINC01296/miR-29c-3p axis in ovarian cancer
por: Xu, Hui, et al.
Publicado: (2020) -
Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia
por: Xu, Ling, et al.
Publicado: (2014) -
Recombinant pre-miR-29b for Alzheimer´s disease therapeutics
por: Pereira, Patrícia A., et al.
Publicado: (2016) -
miR-29 regulates Tet1 expression and contributes to early differentiation of mouse ESCs
por: Cui, Yanhua, et al.
Publicado: (2016) -
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
por: Amodio, Nicola, et al.
Publicado: (2015)